SCH772984

目录号:S7101

SCH772984 Chemical Structure

Molecular Weight(MW): 587.67

SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。

规格 价格 库存 购买数量  
RMB 2210.07 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • 293T cells were transfected with Flag-WT-FBW7. Thirty hours post transfection, cells were pretreated with MG132 and various MEK/ERK inhibitors overnight before harvesting. FBW7 phosphorylation status was examined by immunoblot analysis after immunoprecipitation.

    Cell Research, 2015, 25: 561-573. SCH772984 purchased from Selleck.

    K562 cells were exposed to ERK inhibitor SCH772984 (1 uM, 2 uM, 5 uM) for 48 h. Apoptosis was analyzed by Annexin V-APC labeling.

    Leuk Lymphoma 2014 1, 8. SCH772984 purchased from Selleck.

  • ERK1/2 influences the effects of TGF-β1 on Cdk5 and Bax in PC12 cells. A. Original western blot showing the level of Cdk5 and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. B. Arithmetic means ± SEM (n = 4) of Cdk5 protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. C. Original western blot showing the level of Bax and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) for 2 h. D. Arithmetic means ± SEM (n = 4) of Bax protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) for 2 h. **(p < 0.01), ***(p < 0.001) indicate statistically significant difference.

    Biochem Biophys Res Commun, 2017.. SCH772984 purchased from Selleck.

产品安全说明书

ERK抑制剂选择性比较

生物活性

产品描述 SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。
特性 SCH772984不直接抑制MEK1, MEK2, BRAF, 或 CRAF酶活性。
靶点
ERK2 [1]
(Cell-free assay)
ERK1 [1]
(Cell-free assay)
1 nM 4 nM
体外研究

SCH772984是新型,选择性,ATP竞争性的ERK1/2抑制剂。SCH772984抑制ERK底物p90核糖体S6激酶(T359/S363 磷酸化-RSK)的磷酸化,这种作用存在剂量依赖性。SCH772984也能抑制ERK自身活化环中残基的磷酸化。SCH772984分别抑制约88%和49%BRAF突变型或RAS-突变型肿瘤细胞系,EC50值<500 nM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
2P-ERK2 Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml71TWM2OD1yLkK0JI5O NXHGVGNiOjV|NUC5N|E>
WM-266-4 NH[zXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnRTWM2OD1{MDDuUS=> NHPWSFgzOzZzNEi5PC=>
UACC-62 NUHCfGNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jn[2lEPTB;M{Cgcm0> MXWyN|YyPDh7OB?=
Colo-205 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTEXXlWUUN3ME2zOkBvVQ>? MnPGNlM3OTR6OUi=
SK-Mel-1 MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVewbWJGUUN3ME2zO{BvVQ>? NUjI[WZEOjN4MUS4PVg>
WiDr MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7YTWM2OD1|OTDuUS=> MlrhNlM3OTR6OUi=
M14 NYHSZZFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHHTWM2OD12NzDuUS=> M1TjelI{PjF2OEm4
HT-29 M1LEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfwVFNKSzVyPUWwJI5O NEnY[IEzOzZzNEi5PC=>
8505C NV;4VGlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofTTWM2OD13MDDuUS=> MVmyN|YyPDh7OB?=
HT-144 MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfZOZlKSzVyPU[wJI5O MVKyN|YyPDh7OB?=
SK-Mel-5 NFL4VVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fSPWlEPTB;Nk[gcm0> NYXt[2RLOjN4MUS4PVg>
A375-SM NXy4enZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDLbppKSzVyPUe1JI5O MXqyN|YyPDh7OB?=
SK-Mel-28 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PzPGlEPTB;OEWgcm0> MVeyN|YyPDh7OB?=
LOX Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr4TWM2OD1zMECgcm0> NV\5UpJTOjN4MUS4PVg>
SK-Mel-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFzODDuUS=> M1XpbVI{PjF2OEm4
K1 MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF|MDDuUS=> M1;5blI{PjF2OEm4
Hs-695T Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLXTWM2OD1zNkWgcm0> NFHEUYszOzZzNEi5PC=>
BHT-101 NEXje|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTNyMDDuUS=> M1zL[FI{PjF2OEm4
RPMI-7951 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[xWmlEPTB;M{S0JI5O M3PFOFI{PjF2OEm4
A2058 Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PjT2lEPTB;M{[wJI5O MlexNlM3OTR6OUi=
SK-Hep-1 Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PaW2lEPTB;MUSyNkBvVQ>? M4SwS|I{PjF2OEm4
A673 NXXCU5hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfNTFBKSzVyPUOwNFEhdk1? NFTvN3AzOzZzNEi5PC=>
DBTRG-05MG NHfmNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXZSYZKSzVyPUOwNFEhdk1? MnPZNlM3OTR6OUi=
SW-626 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C0dGlEPTB;M{Ogcm0> Ml7JNlM3OTR6OUi=
LoVo M2nMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\jSGlEPTB;NEegcm0> NYHFNlVjOjN4MUS4PVg>
MiaPaCa NV3GNGZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDVUHh[UUN3ME21N{BvVQ>? NF[2V2szOzZzNEi5PC=>
SW-620 MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f5NmlEPTB;MUC0JI5O NYHjPZBbOjN4MUS4PVg>
CAPAN-1 NWX4NHR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHJT2dKSzVyPUGwOEBvVQ>? MnvnNlM3OTR6OUi=
SW-527 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TxZWlEPTB;MUKxJI5O NFLK[pQzOzZzNEi5PC=>
HCT-116 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL6TWM2OD1zMkigcm0> MUWyN|YyPDh7OB?=
SW-480 MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnQTWM2OD1zNkWgcm0> MVqyN|YyPDh7OB?=
HPAC M1npXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHXeXBYUUN3ME2xO|Ahdk1? NH\GWHkzOzZzNEi5PC=>
OVCAR-5 MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWG2co54UUN3ME2yNFghdk1? NXnYVHRNOjN4MUS4PVg>
AsPc-1 M2LGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ5MDDuUS=> NHG4U40zOzZzNEi5PC=>
A549 M2jzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHFUGdKSzVyPUOyOkBvVQ>? NIfvUHIzOzZzNEi5PC=>
SNU-1 M4TwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HwVGlEPTB;M{W0JI5O NEPQcXkzOzZzNEi5PC=>
HOP62 Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTZ5NjDuUS=> M2LEPVI{PjF2OEm4
H23 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvOPHhxUUN3ME2xNFAxKG6P NGXL[mwzOzZzNEi5PC=>
MB-231 M2TkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPZe3J1UUN3ME2xNFAxKG6P Mo\JNlM3OTR6OUi=
SU.86.86 M4PydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHDSWxtUUN3ME2xNFAyKG6P MkjFNlM3OTR6OUi=
CFPAC-1 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjFcVBjUUN3ME2xNFAyKG6P MWSyN|YyPDh7OB?=
A427 NVTVVWx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e4T2lEPTB;MUSzN{BvVQ>? NGXo[nczOzZzNEi5PC=>
MDAH-2774 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXJTWM2OD1{NkW3JI5O M4LuW|I{PjF2OEm4
NCI-H157 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zLdmlEPTB;M{CwNEBvVQ>? M3nSZ|I{PjF2OEm4
HTB-177 M3L3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfyXZZKSzVyPUOwNFAhdk1? MlPkNlM3OTR6OUi=
UM-UC-3 MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkewTWM2OD1|MECxJI5O M{GwU|I{PjF2OEm4
HCT-8 NGO4OYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\oeVBKSzVyPUOwNFEhdk1? MYqyN|YyPDh7OB?=
Panc-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTNyMEGgcm0> MmDmNlM3OTR6OUi=
DLD-1 NF\iNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTNyMEGgcm0> NInVV20zOzZzNEi5PC=>
HCT-15 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XucWlEPTB;M{CwNUBvVQ>? NHPkZ4czOzZzNEi5PC=>
HL-60 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTNyIH7N MXKyN|YyPDh7OB?=
SK-Mel-2 NHfXOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN2IH7N NF63UY8zOzZzNEi5PC=>
RD NVXxdVV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;tTWM2OD1zMkOgcm0> NX20cXo2OjN4MUS4PVg>
HT-1197 M4SzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LTXmlEPTB;M{G2JI5O MWGyN|YyPDh7OB?=
Molt-3 NInWNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrGTWM2OD14MECgcm0> NV3tNFdiOjN4MUS4PVg>
PA-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7tO5hKSzVyPUGwNFEhdk1? MXGyN|YyPDh7OB?=
Molt-4 NF\SOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\vbVlOUUN3ME2zNFAyKG6P NGrze40zOzZzNEi5PC=>
NCI-H292 M3fuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTlyIH7N NUWwcpUzOjN4MUS4PVg>
A2780 NXHGVGFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7XdWNKSzVyPUG0N{BvVQ>? NEn0R3czOzZzNEi5PC=>
IGROV-1 NXixd3dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPLVWhKSzVyPUG0OkBvVQ>? NIK1SlIzOzZzNEi5PC=>
SK-N-SH MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLDcpJnUUN3ME2xOVAhdk1? NH\aeIQzOzZzNEi5PC=>
N-87 NX3VdVkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNyNzDuUS=> MnPJNlM3OTR6OUi=
H322 M2fJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7NNoJTUUN3ME2zNlUhdk1? MUCyN|YyPDh7OB?=
H716 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLuTWM2OD1|M{Sgcm0> NUKzdYNIOjN4MUS4PVg>
TT M4XPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTRyNjDuUS=> NUXwUpl2OjN4MUS4PVg>
Caki-1 M3HMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnRTWM2OD12NUCgcm0> NW\uVlBHOjN4MUS4PVg>
5637 NH7se4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzxcolKSzVyPU[xNEBvVQ>? MkfiNlM3OTR6OUi=
MB-453 NHX3Z|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33uOmlEPTB;NkeyJI5O NGrNUY8zOzZzNEi5PC=>
RT-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPJUZc5UUN3ME24NVAhdk1? NG\O[XgzOzZzNEi5PC=>
HOP92 NUf6b5BGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTh{MDDuUS=> Mnq4NlM3OTR6OUi=
KG-1 M37FWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fzUmlEPTB;OUCwJI5O M{jtS|I{PjF2OEm4
Hs-294T M1PrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUiyPG5WUUN3ME25OFUhdk1? MWOyN|YyPDh7OB?=
SF-539 NF[4[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrrcFZKSzVyPUGwNFAhdk1? M{i5OlI{PjF2OEm4
U-251 M{CydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr4d4RKSzVyPUGwNFAhdk1? MoDXNlM3OTR6OUi=
MB-468 MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFyMECgcm0> MVOyN|YyPDh7OB?=
HS746T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDiTWM2OD1zMECwJI5O M4iyfVI{PjF2OEm4
SCABER MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3mOYNDUUN3ME2xNFAxKG6P MnTpNlM3OTR6OUi=
MCF-7 NHX0O2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXWTWM2OD1zMECxJI5O NEXPcmQzOzZzNEi5PC=>
CHL-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PGPWlEPTB;MUS2NEBvVQ>? M2W3NFI{PjF2OEm4
U87MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJyMECgcm0> MWCyN|YyPDh7OB?=
SJCRH30 M3rmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXISGVOUUN3ME2yNFAzKG6P NEK3PVEzOzZzNEi5PC=>
ES-2 M{G4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn2XlVKSzVyPUK2OVkhdk1? NH[xXmwzOzZzNEi5PC=>
HT-1376 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q3fWlEPTB;MkiwNEBvVQ>? MXKyN|YyPDh7OB?=
A172 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTNyMECgcm0> M{n1eVI{PjF2OEm4
769P Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvLN|hKSzVyPUOwNFAhdk1? MlHqNlM3OTR6OUi=
NCI-H520 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlriTWM2OD1|MECwJI5O NVX1c4J2OjN4MUS4PVg>
DU145 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnITWM2OD1|MECwJI5O MWeyN|YyPDh7OB?=
K562 M{XU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\nNmNKSzVyPUOwNFAhdk1? MmjDNlM3OTR6OUi=
U-937 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\jVo4zUUN3ME2zNFAxKG6P Moi5NlM3OTR6OUi=
A204 NWHGSpBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWexNm85UUN3ME2zNFAyKG6P MW[yN|YyPDh7OB?=
DAOY MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNyMEGgcm0> MVyyN|YyPDh7OB?=
SF-268 MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnraTWM2OD1|MECxJI5O MWGyN|YyPDh7OB?=
SF-295 M1LkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLjTFRKSzVyPUOwNFEhdk1? MYeyN|YyPDh7OB?=
SNB-19 NH\IOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PvVWlEPTB;M{CwNUBvVQ>? Mn:yNlM3OTR6OUi=
SNB-75 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;1TWM2OD1|MECxJI5O MlHDNlM3OTR6OUi=
U373-MG MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjTTWM2OD1|MECxJI5O NGjwTlAzOzZzNEi5PC=>
786-O MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGryT2pKSzVyPUOwNFEhdk1? MlXGNlM3OTR6OUi=
A498 MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTNyMEGgcm0> MnXxNlM3OTR6OUi=
ACHN MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPOfokzUUN3ME2zNFAyKG6P NHPLb3UzOzZzNEi5PC=>
EKVX NF7OXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDNXI1KSzVyPUOwNFEhdk1? M33PZlI{PjF2OEm4
H226 NVPDSIhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXM[ZNKSzVyPUOwNFEhdk1? NHTTfYwzOzZzNEi5PC=>
H522 NYnkZlI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTNyMEGgcm0> MVuyN|YyPDh7OB?=
HeLa NHf5epVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTNyMEGgcm0> NIrDVGQzOzZzNEi5PC=>
SK-OV-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfuTmdKSzVyPUOwNFEhdk1? NGXjNIQzOzZzNEi5PC=>
Ln Cap MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC3TWM2OD1|MECxJI5O M2LmWFI{PjF2OEm4
PC3 NH3VTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTNyMEGgcm0> MXWyN|YyPDh7OB?=
SNU-16 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7OZXJGUUN3ME2zNFAyKG6P M3v4VVI{PjF2OEm4
FTC-133 M{f2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTlc3JKSzVyPUOwNFEhdk1? MXyyN|YyPDh7OB?=
Ro82-W-1 Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz2VphJUUN3ME2zNFAyKG6P MnLwNlM3OTR6OUi=
Daudi MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTNyMEGgcm0> NIXzOGQzOzZzNEi5PC=>
Jijoye NH3zSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLuTWM2OD1|MECxJI5O NVK0OJhZOjN4MUS4PVg>
Jurkat M4GxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe3bYJKSzVyPUOwNFEhdk1? M4qzSFI{PjF2OEm4
J-82 MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrMU|V2UUN3ME2zNFAyKG6P MmTENlM3OTR6OUi=
TCC-SUP MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHYTWM2OD1|MECxJI5O MVqyN|YyPDh7OB?=
BT-474 NE\mbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTNyMEGgcm0> M2XYZ|I{PjF2OEm4
ZR-75-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LU[WlEPTB;M{CwNUBvVQ>? Ml;CNlM3OTR6OUi=

... Click to View More Cell Line Experimental Data

体内研究 SCH772984按耐受剂量处理移植瘤模型,诱导肿瘤衰退。SCH772984作用于抗BRAF或MEK抑制剂的模型,有效抑制MAPK信号和细胞增殖。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

ERK2 IMAP 酶实验:

SCH772984作用于纯化的ERK2或ERK1,按一式两份进行8点稀释曲线。酶添加到实验板中。与化合物温育,然后加入底物肽和ATP溶液中。384孔板中每孔加入14μl稀释的酶(每组反应含0.3ng活性ERK2)。实验板轻轻震荡混合试剂,然后在室温下温育45分钟。加入60μl of IMAP 结合溶液 (IMAP珠在1X结合缓冲液中按1:2200稀释)终止反应。实验板在室温下再温育0.5小时,使磷酸肽与IMAP珠完全结合。然后在 LJL分析仪上读数。
细胞实验:

[1]

+ 展开
  • Cell lines: BRAF突变型或 RAS突变型肿瘤系
  • Concentrations: ~10 μM
  • Incubation Time: 5 天
  • Method:

    在96孔板中进行细胞增殖实验,细胞按每孔 4,000个的密度接种。接种24小时后,使用DMSO处理细胞,9点IC50稀释 (0.001-10 μM) ,DMSO终浓度为1%。使用ViaLight发光试剂盒5天后,测定存活力。细胞系存活力检测中,使用SCH772984处理细胞4天,然后进行CellTiterGlo发光细胞活力检测。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 裸鼠
  • Formulation: --
  • Dosages: 12.5 mg/kg, 25 mg/kg, 50 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL warmed (23.82 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次加入纯溶剂:
5% DMSO+30% PEG 300+ddH2O
0.6mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 587.67
化学式

C33H33N9O2

CAS号 942183-80-4
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to inhibit Erk1/2 by treating the mice with the inhibitor. by what kind of administration way and at what concentration could it be done?

  • 回答:

    SCH772984 can be administrated by I.P. The dosages can be used as: 12.5 mg/kg, 25 mg/kg, 50 mg/kg. For more detail information please find the paper below: http://cancerdiscovery.aacrjournals.org/content/3/7/742.full

ERK Signaling Pathway Map

Tags: 购买SCH772984 | SCH772984供应商 | 采购SCH772984 | SCH772984价格 | SCH772984生产 | 订购SCH772984 | SCH772984代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID